NASDAQ$KIDS
OrthoPediatrics Corp · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
OrthoPediatrics experienced significant revenue growth, driven by strong domestic performance and international expansion.
OrthoPediatrics reported a 96% increase in total revenue for Q2 2021, reaching $26.7 million, compared to $13.6 million in Q2 2020. The company saw robust growth in both U.S. and international markets, with U.S. revenue increasing by 79% and international revenue increasing by 243%.
- Total revenue increased by 96% year-over-year, reaching $26.7 million.
- U.S. revenue grew by 79%, representing 81.4% of total revenue.
- International revenue increased by 243%, representing 18.6% of total revenue.
- Gross profit margin improved to 76.6% compared to 74.0% in the same period last year.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$26.7M
Revenue by segment
OrthoPediatrics · $26.7M total across 3 segments · Q2 2021
- Trauma and Deformity$17.9M+94.5%67.2%
- Scoliosis$7.66M+99.6%28.7%
- Sports Medicine/Other$1.11M+105.8%4.1%
Forward guidance
The Company is increasing its full year revenue guidance range to $97 to $101 million, up from $94 to $98 million, representing 36% to 42% growth over 2020 revenue.
Tailwinds
- Increased full year 2021 revenue guidance from $94-$98 million to $97-$101 million
- Strong momentum in the U.S.
- Expecting 36% to 42% growth over 2020 revenue.
Headwinds
- Potential headwinds resulting from the COVID-19 Delta variant.
- Expect regional variability to persist in international markets.
- Hospitals continue to work through backlogs.
- Countries face challenges with COVID-19 surges.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro